Sudarshan Pharma Industries: FY26 growth, new manufacturing assets, and an export ambition

Sudarshan Pharma Industries Limited (SPIL) presented a picture of a company trying to scale fast across two connected arenas: pharmaceutical products and specialty chemicals. The April 2026 investor presentation positions the group as a trading, sourcing, and manufacturing platform that is moving toward deeper vertical integration, supported by newer facilities, subsidiaries, and a stated push into regulated export markets.

On the financial side, consolidated performance in FY26 improved meaningfully. Revenue from operations increased to INR 703.06 crore in FY26 from INR 505.05 crore in FY25. Consolidated profit after tax rose to INR 23.30 crore from INR 15.88 crore. The quarterly data shared for FY26 also indicates improving profitability through the year, with the March 2026 quarter showing stronger margins than the earlier quarters presented.

What the company says it does today

SPIL describes itself as a specialty chemicals and pharmaceutical trading and manufacturing company founded in 2008. Its current positioning leans on two ideas.

First, it operates across multiple product layers of the pharma value chain, beginning from raw materials and intermediates and moving to APIs and finished formulations. The presentation explicitly describes a plan for vertical integration that spans chemical raw materials for pharmaceuticals, intermediates, API manufacturing and import, finished formulations and formulation development research, and branded generics.

Second, it highlights a global reach. The presentation notes that products have been exported to the UK, Australia, Uzbekistan, Syria, Oman, Taiwan, and MENA regions, and also lists a broader set of targeted geographies including Europe and the USA.

The company also lists a wide range of customers across pharma and chemicals, including names such as Intas, SRF, Astral Pipes, DuPont, Reliance, Bayer, Akzo Nobel, Biocon, Cipla, Zydus, Takeda, Lupin, Sun Pharma, and others. The presentation does not quantify revenue concentration or order book contribution from these clients.

Manufacturing footprint and capability build-out

A key element of the story is the build-out of manufacturing infrastructure.

The Hyderabad unit is positioned as a bulk drug and intermediate manufacturing facility. SPIL states that the unit has developed about 50 potential API key starting materials and has commercial technology, with some key starting materials holding patent rights. It also notes that intermediates are currently manufactured at commercial scale with regulatory documentation support, and that execution will also be done at a contract manufacturing GMP facility in Hyderabad.

The company also highlights that the Hyderabad manufacturing facility has achieved GMP certification for manufacturing API intermediates and APIs, along with ISO 9001:2015 certification for quality management systems.

Another operational pillar is the Palghar plant in Maharashtra, described as Unit 2. The facility covers testing, dispensing, batch manufacturing, packaging, storage, and dispatch of finished products. The presentation cites an oral liquid production section with a 1,000-litre capacity tank that can produce 2,000 litres per shift, scalable to 6,000 litres across two shifts. The company also states it has approvals for 50 products for both domestic and international markets, across categories such as antibiotics, cough syrups, antipyretics, antifungals, antiallergics, and multivitamins.

Financial performance: FY26 and quarterly progression

The presentation provides both annual consolidated financials and a quarterly P and L snapshot.

Consolidated annual performance

In FY26, consolidated revenue from operations was INR 703.06 crore. Total income was INR 717.77 crore, supported by other income of INR 8.71 crore. Profit before tax was INR 30.54 crore and profit after tax was INR 23.30 crore.

The cost structure shown suggests a large share of activity is trading-led, with purchase of stock-in-trade at INR 652.13 crore in FY26, compared to cost of materials consumed at INR 39.06 crore.

Quarterly profitability trend

In the March 2026 quarter, revenue from operations was INR 220.92 crore. Gross profit was INR 30.87 crore, with a gross profit margin of 13.97%. EBITDA was INR 20.19 crore, with an EBITDA margin of 9.14%. Profit after tax for the quarter was INR 10.73 crore, implying a PAT margin of 4.86%.

Relative to earlier quarters shown (June 2025 to December 2025), margins appear to have strengthened by the end of the period.

Financial summary

Balance sheet signals: scale-up with higher working capital and borrowing

The FY26 consolidated balance sheet shows a sharp expansion in scale.

Total assets increased to INR 641.75 crore at March 31, 2026, from INR 402.41 crore in FY25. Property, plant and equipment rose to INR 96.03 crore from INR 29.91 crore, consistent with the company’s focus on increasing manufacturing capabilities.

However, the same balance sheet highlights heavy working capital and borrowings. Short-term borrowings increased to INR 255.11 crore in FY26 from INR 160.27 crore in FY25. Trade receivables rose to INR 233.34 crore from INR 160.16 crore. Inventories increased to INR 218.74 crore from INR 140.48 crore.

Cash and cash equivalents were INR 1.13 crore at March 31, 2026. The presentation does not provide an operating cash flow statement, so cash conversion cannot be validated from this document alone.

Subsidiaries and the Ratna Lifescience turnaround

SPIL lists several subsidiaries, including Rathā LifeScience Private Limited and Life Science Chemical Private Limited (both wholly owned), and Ishwari Healthcare Private Limited (51% ownership). It also mentions Sudarshan Pharma Industries Private Limited, Singapore; Sudarshan Pharma Lifescience Private Limited; and Cibachem General Trading LLC, Dubai as wholly owned subsidiaries, and Sudarshan Mave n Pharma Private Limited as 70% owned.

One subsidiary case study is Ratna Lifescience, presented as a turnaround story.

Ratna Lifescience revenue from operations increased from INR 0.02 crore in FY23 to INR 2.15 crore in FY24, INR 9.22 crore in FY25, and INR 35.30 crore in FY26. Profit after tax moved from negative INR 0.87 crore in FY23 to positive INR 0.51 crore in FY24, INR 7.1 crore in FY25, and INR 7.8 crore in FY26. The company states that Ratna Life was loss-making prior to takeover and has since become profitable.

The presentation does not reconcile how much of the consolidated results are driven by Ratna versus other divisions, and it does not share subsidiary-level balance sheets.

Products: broad portfolio, limited quantified mix

The presentation lists products across specialty green chemicals such as acetonitrile, THF, 1,4-dioxane, DMF/DMSO, meta xylene, n-hexane, diethanolamine, and NMP.

In pharma, it states that out of 96 products, 56 are registered under the R trade mark. It also highlights a mouth-dissolving strip category under the Love Bird R brand, with five products. It describes HART KIT LD as a cardiac first-aid product, and SET DOWN as a combination of allopathy and ayurveda for constipation.

Top-selling brands mentioned include METFOCAL, PULMORELIEF AX, RD MAC DSR, SET DOWN, ENAMOL SP Hem D3, JIVAN KIT, and Infart Q-10. The presentation also references Vimac in the context of earlier branded product introductions.

Beyond naming products, no revenue, gross margin, or volume split is provided by product or division in this presentation.

Export opportunity: a quantified near-term target

The export roadmap is one of the few areas where the presentation provides explicit numeric targets.

For FY25-26, SPIL states it achieved total export turnover of INR 21.85 crore, with a focus on its own manufacturing API products including oncology and finished formulations, prioritizing product registration and using loan licenses with manufacturers for cost-effective supply.

For FY26-27, the company states it wants to strengthen segments and target regulated and semi-regulated markets, expand its API range toward higher value products, and boost exports for regulated markets like Europe and the USA. It states a minimum export target of INR 100 crore for FY26-27.

For FY27-28, it states it wants to strengthen OTC and regulated markets, form depots in various countries for stock and sale, and increase finished formulation registrations in regulated markets.

What stands out and what remains unclear

SPIL’s presentation makes a clear attempt to connect strategy with assets and market opportunity. The China dependence narrative and the government focus on bulk drugs and critical APIs are used as context for why domestic API and intermediate manufacturing can matter.

At the same time, several items remain difficult to validate from the document alone. The company does not provide segment-level financials, export share as a percentage of revenue, capacity utilization, customer concentration, or cash flow metrics. The balance sheet indicates a working capital intensive structure with higher borrowings, and the quarterly finance cost has increased, which can become a constraint if growth requires more capital.

Takeaways for investors

FY26 consolidated results show higher revenue and a sharp increase in PAT, along with improving quarterly margins by March 2026. The company is also demonstrating activity on multiple operational fronts, including the Hyderabad unit certifications, Palghar facility scale-up, and a stated export expansion plan with a numeric FY26-27 target.

The biggest analytical gap from this presentation is the absence of segment-level revenue and margin disclosures. Without that, investors can see consolidated growth, but cannot independently validate which parts of the portfolio are driving profitability and whether the margin expansion is sustainable.